Previous close | 28.75 |
Open | 28.63 |
Bid | 27.61 x 100 |
Ask | 27.76 x 200 |
Day's range | 27.57 - 28.78 |
52-week range | 19.34 - 63.08 |
Volume | |
Avg. volume | 494,512 |
Market cap | 1.386B |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.59 |
Earnings date | 24 Apr 2024 - 29 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 56.75 |
Morphic (MORF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Over the last year, a good number of insiders have significantly increased their holdings in Morphic Holding, Inc...
Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory DiseasesWALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a p